In a recent study, many trials leading to the approval of a targeted therapy were not fully transparent about the risk for adverse events (AEs), and most were deficient in reporting recurrent and late toxicities. Underreporting of AEs might be more frequent with targeted treatments than conventional chemotherapies.  AEs associated with targeted agents persist longer may not be not fully captured by physicians. (Clinical Oncology)